Search - tctmd.com

Displaying 41 - 60 of 414

Sort: Relevancy | Date

News Conference News TCT 2024

Bleeding After MCS in DanGer Shock: When, Where, and What to Do?

Caitlin E. Cox

October 31, 2024

Presentation TCT 2024

DANGER Shock: Impella versus Standard Card for STEMI Patients with Cardiogenic Shock

Presenter: Jacob Moeller

October 30, 2024

Presentation TCT 2024

TCT 272: DANGER Shock Trial Versus Real-World Use of Microaxial Flow Pump in STEMI-Related Cardiogenic Shock

Presenter: Jack Jnani

October 29, 2024

Presentation TCT 2024

TCT 273: DanGer Shock-Like Profile Predicts the Outcome of Patients With ST-Elevation Myocardial Infarction Related Cardiogenic Shock

Presenter: Norman Mangner

October 29, 2024

Presentation TCT 2024

TCT 269: Insights From the Danger-SHOCK and ECLS-Shock Trials: A Comparative Analysis

Presenter: Giuseppe Tarantini

October 29, 2024

Presentation TCT 2024

Results of DanGer Shock: Risks and Benefits of MCS for Cardiogenic Shock Put Into Perspective

Presenter: Jacob Moeller

October 29, 2024

Presentation TCT 2024

Ways in Which DanGer Will and Will Not Influence Clinical Practice in the EU

Presenter: Jose Henriques

October 29, 2024

Presentation TCT 2024

A Mandate to Generate Evidence for the Use of Temporary Support Devices in Decompensated Chronic Heart Failure Shock

Presenter: Jane Wilcox

October 29, 2024

Presentation TCT 2024

Ways in which DanGer Will and Will Not Influence Clinical Practice in the US

Presenter: David Morrow

October 29, 2024

Presentation TCT 2024

TCT 267: Impact of Microaxial Flow Pump on Central Hemodynamics and Use of Vasoactive Drugs During Intensive Care After Infarct-Related Cardiogenic Shock: A Secondary Analysis of the Danger Shock Trial

Presenter: Nanna Louise Junker Udesen

October 29, 2024

Presentation TCT 2024

TCT 265: Bleedings Related to Use of Microaxial Flow Pump in Cardiogenic Shock: A Secondary Analysis of Danger Shock

Presenter: Rikke Sørensen

October 29, 2024

Presentation TCT 2024

TCT 1464: A TAVI With a Dangerous Twist

Presenter: George Besis

October 29, 2024

Presentation TCT 2024

TCT 791: Do Females Have Less Effect of Mircoaxial Flow Pump in Infarct Related Cardiogenic Shock: A Secondary Analysis of the Danger Shock Trial

Presenter: Norman Mangner

October 29, 2024

Presentation TCT 2024

Optimizing Outcomes: Contemporary Practices for Vascular Management

Presenter: Rhian Davies

October 28, 2024

Presentation TCT 2024

New England Journal of Medicine RCT: DanGer Shock: Operationalizing the Data

Presenter: Babar Basir

October 28, 2024

Presentation TCT 2024

Principal PI Perspectives on the New England Journal of Medicine RCT: DanGer Shock

Presenter: Jacob Moeller

October 28, 2024

Presentation TCT 2024

Optimizing Outcomes: Contemporary Practices for Patient Management

Presenter: Navin Kapur

October 28, 2024

News Conference News TCT 2024

New DanGer Shock Data: Hemodynamics, Renal Dysfunction, and Bleeding

Caitlin E. Cox

October 28, 2024

Presentation TCT 2024

Impact of Microaxial Flow Pump on Central Hemodynamics and Use of Vasoactive Drugs During Intensive Care After Infarct-Related Cardiogenic Shock: A Secondary Analysis of the DanGer Shock Trial

Presenter: Nanna Louise Junker Udesen

October 27, 2024

Presentation TCT 2024

Microaxial Flow Pump Use and Renal Outcomes in Cardiogenic Shock: An Analysis of the DanGer Shock Trial

Presenter: Jacob Moeller

October 27, 2024

Advertisement

Bleeding After MCS in DanGer Shock: When, Where, and What to Do?

DANGER Shock: Impella versus Standard Card for STEMI Patients with Cardiogenic Shock

TCT 272: DANGER Shock Trial Versus Real-World Use of Microaxial Flow Pump in STEMI-Related Cardiogenic Shock

TCT 273: DanGer Shock-Like Profile Predicts the Outcome of Patients With ST-Elevation Myocardial Infarction Related Cardiogenic Shock

TCT 269: Insights From the Danger-SHOCK and ECLS-Shock Trials: A Comparative Analysis

Results of DanGer Shock: Risks and Benefits of MCS for Cardiogenic Shock Put Into Perspective

Ways in Which DanGer Will and Will Not Influence Clinical Practice in the EU

A Mandate to Generate Evidence for the Use of Temporary Support Devices in Decompensated Chronic Heart Failure Shock

Ways in which DanGer Will and Will Not Influence Clinical Practice in the US

TCT 267: Impact of Microaxial Flow Pump on Central Hemodynamics and Use of Vasoactive Drugs During Intensive Care After Infarct-Related Cardiogenic Shock: A Secondary Analysis of the Danger Shock Trial

TCT 265: Bleedings Related to Use of Microaxial Flow Pump in Cardiogenic Shock: A Secondary Analysis of Danger Shock

TCT 1464: A TAVI With a Dangerous Twist

TCT 791: Do Females Have Less Effect of Mircoaxial Flow Pump in Infarct Related Cardiogenic Shock: A Secondary Analysis of the Danger Shock Trial

Optimizing Outcomes: Contemporary Practices for Vascular Management

New England Journal of Medicine RCT: DanGer Shock: Operationalizing the Data

Principal PI Perspectives on the New England Journal of Medicine RCT: DanGer Shock

Optimizing Outcomes: Contemporary Practices for Patient Management

New DanGer Shock Data: Hemodynamics, Renal Dysfunction, and Bleeding

Impact of Microaxial Flow Pump on Central Hemodynamics and Use of Vasoactive Drugs During Intensive Care After Infarct-Related Cardiogenic Shock: A Secondary Analysis of the DanGer Shock Trial

Microaxial Flow Pump Use and Renal Outcomes in Cardiogenic Shock: An Analysis of the DanGer Shock Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content